Discovery of N-(1-(3-fluorobenzoyl)-1H-indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B

References

• Schapira AH, Bezard E, Brotchie J, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 2006;5:845–54.
   PubMed Web of Science ®Google Scholar
• Barker RA, Stacy M, Brundin P. A new approach to disease-modifying drug trials in Parkinson's disease. J Clin Investig 2013;123:2364–5.
   PubMed Web of Science ®Google Scholar
• Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. J Neurochem 2016;139:318–24.
   PubMed Web of Science ®Google Scholar
• Greenamyre JT, Hastings TG. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science (New York, N.Y.) 2004;304:1120–2.
   PubMed Web of Science ®Google Scholar
• Alexander GE. Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dial Clin Neurosci 2004;6:259–80.
   PubMedGoogle Scholar
• Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57–87.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Dalvie DK, Castagnoli N, Taylor TJ. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol 2001;14:1139–62.
   PubMed Web of Science ®Google Scholar
• Silverman RB. Radical ideas about monoamine oxidase. Acc Chem Res 1995;28:335–42.
   Web of Science ®Google Scholar
• Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 1999;22:197–217.
   PubMed Web of Science ®Google Scholar
• Robottom BJ. Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. Patient Prefer Adherence 2011;5:57–64.
   PubMed Web of Science ®Google Scholar
• Lohle M, Reichmann H. Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. BMC Neurol 2011;11:112.
   PubMed Web of Science ®Google Scholar
• Rascol O, Perez-Lloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. Mov Disord 2015;30:1451–60.
   PubMed Web of Science ®Google Scholar
• Robakis D, Fahn S. Defining the role of the monoamine oxidase-B inhibitors for Parkinson's disease. CNS Drugs 2015;29:433–41.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy 2007;27:174S–85S.
   PubMed Web of Science ®Google Scholar
• Finberg JP. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther 2014;143:133–52.
   PubMed Web of Science ®Google Scholar
• Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 2011;164:1357–91.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Rosa MM, Abreu D, Ferreira JJ. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. Neurodegener Dis Manage 2015;5:481–96.
   PubMed Web of Science ®Google Scholar
• Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67:S18–S23.
   PubMed Web of Science ®Google Scholar
• Caccia C, Salvati P, Rossetti S, Anand R. 2.207 Safinamide: beyond MAO-B inhibition. Parkinson Relat Disord 2007;13:S99.
   Web of Science ®Google Scholar
• Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs 2000;8:570–9.
   Google Scholar
• Pevarello P, Bonsignori A, Dostert P, et al. Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. J Med Chem 1998;41:579–90.
   PubMed Web of Science ®Google Scholar
• Borroni E, Bohrmann B, Grueninger F, et al. Sembragiline: a novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 2017;362:413–23.
   PubMed Web of Science ®Google Scholar
• Nave S, Doody RS, Boada M, et al. Sembragiline in moderate Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase II trial (MAyflOwer RoAD). J Alzheimers Dis 2017;58:1217–28.
   PubMed Web of Science ®Google Scholar
• Jo S, Yarishkin O, Hwang YJ, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. Nat Med 2014;20:886–96.
   PubMed Web of Science ®Google Scholar
• Choi JW, Jang BK, Cho NC, et al. Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. Bioorg Med Chem 2015;23:6486–96.
   PubMed Web of Science ®Google Scholar
• Park HR, Kim J, Kim T, et al. Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease. Bioorg Med Chem 2013;21:5480–7.
   PubMed Web of Science ®Google Scholar
• Yeon SK, Choi JW, Park JH, et al. Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy. Bioorg Med Chem 2018;26:232–44.
   PubMed Web of Science ®Google Scholar
• Nam MH, Park M, Park H, et al. Indole-substituted benzothiazoles and benzoxazoles as selective and reversible MAO-B inhibitors for treatment of Parkinson's disease. ACS Chem Neurosci 2017;8:1519–29.
   PubMed Web of Science ®Google Scholar
• Carradori S, Silvestri R. New frontiers in selective human MAO-B inhibitors. J Med Chem 2015;58:6717–32.
   PubMed Web of Science ®Google Scholar
• Reis J, Cagide F, Chavarria D, et al. Discovery of new chemical entities for old targets: insights on the lead optimization of chromone-based monoamine oxidase B (MAO-B) inhibitors. J Med Chem 2016;59:5879–93.
   PubMed Web of Science ®Google Scholar
• Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007;50:5848–52.
   PubMed Web of Science ®Google Scholar
• Desideri N, Fioravanti R, Proietti Monaco L, et al. Alcaro, 1,5-diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors. Eur J Med Chem 2013;59:91–100.
   PubMed Web of Science ®Google Scholar
• Tzvetkov NT, Hinz S, Küppers P, et al. Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency. J Med Chem 2014;57:6679–703.
   PubMed Web of Science ®Google Scholar
• Carradori S, Secci D, Bolasco A, et al. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential. Expert Opin Ther Pat 2012;22:759–801.
   PubMed Web of Science ®Google Scholar
• Sharma V, Kumar P, Pathak D. Biological importance of the indole nucleus in recent years: a comprehensive review. J Heterocycl Chem 2010;47:491–502.
   Web of Science ®Google Scholar
• Zdrazil B, Guha R. The rise and fall of a scaffold: a trend analysis of scaffolds in the medicinal chemistry literature. J Med Chem 2018;61:4688–703.
   PubMed Web of Science ®Google Scholar
• Balsa D, Fernandez-Alverez E, Tipton KF, Unzeta M. Monoamine oxidase inhibitory potencies and selectivities of 2-[N-(2-propynyl)-aminomethyl]-1-methyl indole derivatives. Biochem Soc Trans 1991;19:215–8.
   PubMed Web of Science ®Google Scholar
• Sasidharan R, Manju SL, Ucar G, et al. Identification of indole-based chalcones: discovery of a potent, selective, and reversible class of MAO-B inhibitors. Archiv Der Pharm 2016;349:627–37.
   PubMed Web of Science ®Google Scholar
• Gurkan AS, Karabay A, Buyukbingol Z, et al. Syntheses of novel indole lipoic acid derivatives and their antioxidant effects on lipid peroxidation. Archiv Der Pharm 2005;338:67–73.
   PubMed Web of Science ®Google Scholar
• Smaill JB, Gonzales AJ, Spicer JA, et al. Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido[3,4-d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family. J Med Chem 2016;59:8103–24.
   PubMed Web of Science ®Google Scholar
• Li B, Ma J, Xie W, et al. Regioselective C2 oxidative olefination of indoles and pyrroles through cationic rhodium(III)-catalyzed C–H bond activation. Chemistry 2013;19:11863–8.
   PubMed Web of Science ®Google Scholar
• Jiang X, Tiwari A, Thompson M, et al. A practical method for N-methylation of indoles using dimethyl carbonate. Org Process Res Dev 2001;5:604–8.
   Web of Science ®Google Scholar
• Carter MC, Cockerill GS, Guntrip SB, et al. Preparation of 6-(thiomorpholinomethylfuranyl)-4-quinazolinamines as protein tyrosine kinase inhibitors. UK: Glaxo Group Ltd.; 2000.
   Google Scholar
• Cho I-H, Lim J-W, Noh J-Y, et al. Preparation of 1H-indoles as a highly selective cyclooxygenase-2 inhibitors. S. Korea: Cheil Jedang Corporation; 2003.
   Google Scholar
• T, Ishikawa K, Miwa M, Seto, et al. Fused pyrimidines as growth factor receptor tyrosine kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. Japan: Takeda Pharmaceutical Company Limited; 2007.
   Google Scholar
• Ple P, Jung FH. Preparation of quinazoline derivatives for use in treatment of cell proliferative disorders or disease assocd. with angiogenesis and/or vascular permeability. Sweden/UK: AstraZeneca AB/AstraZeneca UK Limited; 2006.
   Google Scholar
• Thomson SP, Davies RT, Allanson NM, et al. Preparation of indolizinyloxoacetamides and related compounds as medical and agrochemical fungicides. Manchester (UK): F2G Ltd.; 2006.
   Google Scholar
• Son SY, Ma J, Kondou Y, et al. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA 2008;105:5739–44.
   PubMed Web of Science ®Google Scholar
• Sastry GM, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 2013;27:221–34.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49.
   PubMed Web of Science ®Google Scholar
• Ramadas K, Srinivasan N. Iron-ammonium chloride – a convenient and inexpensive reductant. Synth Commun 1992;22:3189–95.
   Web of Science ®Google Scholar
• Happe K. Monoamine oxidase inhibitors. In: Enna SJ, Bylund DB, eds. xPharm: the comprehensive pharmacology reference. New York: Elsevier; 2007:1–3.
   Google Scholar